{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:53:30Z","timestamp":1791550410367,"version":"4.3.4"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002338","name":"Ministry of Education of the People's Republic of China","doi-asserted-by":"publisher","award":["ARSBIC-B-202405"],"award-info":[{"award-number":["ARSBIC-B-202405"]}],"id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ctrv.2026.103138","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:11:04Z","timestamp":1776575464000},"page":"103138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making"],"prefix":"10.1016","volume":"146","author":[{"given":"Shengliang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjiu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1721-0341","authenticated-orcid":false,"given":"Quanxing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctrv.2026.103138_b0005","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"7689","key":"10.1016\/j.ctrv.2026.103138_b0010","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103138_b0015","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103138_b0020","first-page":"e31","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (amutMap)","volume":"10","author":"Midha","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103138_b0025","doi-asserted-by":"crossref","first-page":"576","DOI":"10.5306\/wjco.v5.i4.576","article-title":"Review of the Current Targeted Therapies for Non-Small-Cell Lung Cancer","volume":"5","author":"Nguyen","year":"2014","journal-title":"World J Clin Oncol"},{"issue":"36","key":"10.1016\/j.ctrv.2026.103138_b0030","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"PNAS"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103138_b0035","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103138_b0040","first-page":"311","article-title":"Not all EGFR Mutations are created Equal","volume":"11","author":"Kobayashi","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103138_b0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103138_b0050","article-title":"Distinct clinical course of EGFR-mutant resected lung cancers: results from the Lung Cancer Mutation Consortium","volume":"30(15_suppl):7525","author":"D'Angelo","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103138_b0055","first-page":"292","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103138_b0060","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/neuonc\/noq076","article-title":"EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer","volume":"12","author":"Eichler","year":"2010","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103138_b0065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10555-010-9209-4","article-title":"Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation","volume":"29","author":"Suda","year":"2010","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103138_b0070","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103138_b0075","first-page":"261","volume":"16","author":"Suda","year":"2015","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103138_b0080","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11060-008-9531-7","article-title":"Relationship between brain metastasis location and EGFR mutation in non-small cell lung cancer","volume":"152","author":"Ma","year":"2021","journal-title":"J Neurooncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103138_b0085","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103138_b0090","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103138_b0095","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103138_b0100","article-title":"Neoadjuvant Osimertinib for Resectable EGFR-Mutant Non-Small Cell Lung Cancer: a phase 2 Study","volume":"42(16):JCO2301810","author":"Spicer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ctrv.2026.103138_b0105","first-page":"1883","article-title":"Neoadjuvant Osimertinib in patients with Stage II-IIIA EGFR-Mutant Non-Small Cell Lung Cancer: a phase 2 Trial","volume":"42","author":"Lv","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103138_b0110","article-title":"Histological transformation of EGFR mutant NSCLC: a narrative review","volume":"109","author":"Zhang","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103138_b0115","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103138_b0120","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"issue":"10308","key":"10.1016\/j.ctrv.2026.103138_b0125","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010)","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103138_b0130","article-title":"EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer","volume":"6","author":"Dong","year":"2017","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103138_b0135","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00280-012-1929-4","article-title":"Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer","volume":"70","author":"Togashi","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"20","key":"10.1016\/j.ctrv.2026.103138_b0140","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early evidence of Clinical Brain Metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103138_b0145","article-title":"CNS Response to Osimertinib Versus Standard Epidermal Growth factor Receptor Tyrosine Kinase Inhibitors in patients with Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"36(33):JCO2018783118","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103138_b0150","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103138_b0155","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0003-4975(95)00537-U","article-title":"Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. lung cancer Study Group","volume":"60","author":"Ginsberg","year":"1995","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103138_b0160","first-page":"411","article-title":"Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer","volume":"11","author":"Chi","year":"2010","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103138_b0165","first-page":"1064","article-title":"Outcomes after lobectomy using thoracoscopy vs thoracotomy","volume":"143","author":"Paul","year":"2013","journal-title":"Chest"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103138_b0170","first-page":"e299","article-title":"Clinically relapsed disease of resected lung adenocarcinoma with epidermal growth factor receptor mutation","volume":"28","author":"Suda","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103138_b0175","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103138_b0180","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/JTO.0b013e318202bffe","article-title":"Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations","volume":"6","author":"Janjigian","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103138_b0185","doi-asserted-by":"crossref","first-page":"6534","DOI":"10.21037\/jtd-23-1323","article-title":"Efficacy of platinum-based adjuvant chemotherapy for epidermal growth factor receptor-mutant lung adenocarcinoma","volume":"15","author":"Onodera","year":"2023","journal-title":"J Thorac Dis"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103138_b0190","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study","volume":"19","author":"Zhong","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103138_b0195","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1200\/JCO.20.01820","article-title":"Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: final overall Survival Analysis of CTONG1104 phase III Trial","volume":"39","author":"Zhong","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103138_b0200","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.21.01729","article-title":"Randomized phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for patients with Completely Resected Stage II-IIIA Non-Small-Cell Lung Cancer with EGFR Mutation (IMPACT)","volume":"40","author":"Tsuboi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103138_b0205","article-title":"Adjuvant Gefitinib Versus Cisplatin\/Vinorelbine in Japanese patients with Completely Resected EGFR-Mutated Stage II\u2013IIIA Non\u2013Small-Cell Lung Cancer: Subanalysis of a phase III Trial (IMPACT)","volume":"39(15_suppl):8522","author":"Kato","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103138_b0210","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S2213-2600(21)00134-X","article-title":"Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial","volume":"9","author":"He","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ctrv.2026.103138_b0215","article-title":"Icotinib as Adjuvant Therapy in Stage IB EGFR-Mutant Non-Small Cell Lung Cancer: the CORIN Trial","volume":"41(16_suppl):8520","author":"Xia","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103138_b0220","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103138_b0225","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103138_b0230","article-title":"Disease-free survival and central nervous system recurrence with adjuvant osimertinib in patients with EGFR-mutated stage IB-IIIA non-small cell lung cancer: Updated results from the phase III ADAURA trial","volume":"41(suppl","author":"Wu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103138_b0235","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall Survival with Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103138_b0240","first-page":"5226","article-title":"Health-Related Quality of Life Outcomes in patients with Resected Epidermal Growth factor Receptor-Mutated Non-Small Cell Lung Cancer who Received Adjuvant Osimertinib in the phase III ADAURA Trial","volume":"28","author":"Vansteenkiste","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103138_b0245","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jtho.2023.05.015","article-title":"Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in patients with EGFR-Mutated Stage IB to IIIA Non-Small Cell Lung Cancer from the phase III ADAURA Trial","volume":"18","author":"Herbst","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103138_b0250","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jtho.2021.10.014","article-title":"Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC","volume":"17","author":"Wislez","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"26","key":"10.1016\/j.ctrv.2026.103138_b0255","first-page":"3061","article-title":"Deconstructing ADAURA: it is Time to Forgo Adjuvant Platinum-based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (except with RB Alterations?) when adopting Adjuvant Osimertinib","volume":"40","author":"Roye","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103138_b0260","article-title":"Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in patients with Resected EGFR Mutation-positive Non-small Cell Lung Cancer","volume":"13","author":"Guan","year":"2023","journal-title":"Front Oncol"},{"issue":"25","key":"10.1016\/j.ctrv.2026.103138_b0275","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1200\/JCO.19.00075","article-title":"Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): a Randomized phase II Study","volume":"37","author":"Zhong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103138_b0280","first-page":"5","article-title":"Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial","volume":"8","author":"Zhong","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"suppl 10","key":"10.1016\/j.ctrv.2026.103138_b0285","first-page":"S2","article-title":"Perioperative osimertinib in patients with resectable EGFR-mutated non-small cell lung cancer: a phase II trial","volume":"19","author":"Chen","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103138_b0290","article-title":"Neoadjuvant Osimertinib with or without Chemotherapy in Resectable EGFR-Mutated NSCLC: the phase III NeoADAURA Trial","volume":"43(16_suppl):8000","author":"Chaft","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103138_b0295","doi-asserted-by":"crossref","unstructured":"Chaft JE, Garon EB, Wakelee H, et al. Neoadjuvant osimertinib with or without chemotherapy in resectable EGFR-mutated non-small cell lung cancer. J Clin Oncol. Published online June 2, 2025. doi:10.1200\/JCO-25-00883.","DOI":"10.1200\/JCO-25-00883"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103138_b0300","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103138_b0305","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"issue":"7655","key":"10.1016\/j.ctrv.2026.103138_b0310","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103138_b0450","first-page":"1245","article-title":"Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial","volume":"16","author":"Zhou","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103138_b0495","article-title":"Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer","author":"Gale","year":"2025","journal-title":"Nat Med"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:52:07Z","timestamp":1778745127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":62,"alternative-id":["S0305737226000526"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103138","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103138"}}